Clover Biopharmaceuticals, Ltd. (stock code: 02197) submitted its monthly return for the period ended January 31, 2026. The filing indicates that the company’s authorized share capital remained at 2,000,000,000 shares (USD0.0001 par value each), totaling USD200,000 with no changes from the previous month.

The total number of issued ordinary shares increased from 1,297,836,552 to 1,298,037,427, reflecting a net addition of 200,875 shares. No treasury shares were issued or canceled during the period. The company confirmed that it continues to meet the applicable public float requirement.

According to the document, share options under Clover Biopharmaceuticals’ Pre-IPO and Post-IPO Share Option Plans were partially exercised, resulting in new shares and total funds raised of HKD19,998 from these exercises. The filing also confirms that all relevant transactions complied with the applicable listing rules and regulatory requirements.